Roche Holding stock slips after CHMP backs paediatric Ocrevus

Roche Holding AG stock (ISIN CH0012032048) ended the session on the SIX Swiss Exchange lower on September 18, 2026, despite a fresh regulatory milestone for its multiple sclerosis medicine Ocrevus in paediatric patients aged 10 years and older.Interactive Investor

CHMP backs paediatric use of Ocrevus

On September 18, 2026, Roche announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion recommending approval of Ocrevus intravenous infusion for paediatric patients aged 10 years and older with relapsing forms of multiple sclerosis.Globenewswire The company highlighted that the positive CHMP opinion is based on the phase 3 OPERETTA 2 study, in which Ocrevus demonstrated non-inferiority in relapse control and superiority over fingolimod in suppressing brain lesions in paediatric patients.Yahoo Finance

According to Interactive Investor's brief on the decision dated September 18, 2026, the CHMP opinion covers children and adolescents aged 10 years and older with relapsing forms of multiple sclerosis and is based on data showing that Ocrevus reduced the risk of relapses by 48 percent compared with standard-of-care therapy in the phase 3 OPERETTA 2 study.Interactive Investor The company also noted that safety in children and adolescents was aligned with Ocrevus' established safety profile across more than 525,000 adult patients worldwide, reinforcing its potential to expand Roche's neurology franchise in Europe.Yahoo Finance

Stock reaction and recent price levels

Despite the regulatory progress, Roche Holding stock closed at CHF364.80 on the SIX Swiss Exchange on September 18, 2026, down 1.0 percent for the day, indicating that investors took profits after strong gains over the past year.Interactive Investor The same source notes that the shares are up 33 percent over the past 12 months, illustrating a substantial recovery in investor confidence compared with their level one year earlier.Interactive Investor

A separate real-time market snapshot from CNBC shows Roche Holding AG shares trading at CHF356.80 at 5:35 p.m. CEST, down CHF4.40 or 1.22 percent on the day, underlining that the stock has recently experienced short-term pressure even as the longer-term trend remains positive.CNBC A German-language market report from finanzen.ch, summarizing trading on September 18, 2026, states that Roche shares fell 0.3 percent to CHF360.00 at 4:28 p.m. on SIX, with an intraday low of CHF358.50, an opening price of CHF358.60 and trading volume of 1,096,072 shares.finanzen.ch

That same finanzen.ch report notes that Roche's 52-week high stands at CHF375.80, reached on August 26, 2026, meaning that the CHF360.00 trading level discussed in the article is 4.39 percent below the yearly high.finanzen.ch The same source indicates that the share price is 29.94 percent above the 52-week low, showing that investors who bought at the low have seen almost a 30 percent gain over the past year.finanzen.ch

Analyst consensus and valuation backdrop

Roche's valuation is supported by a generally constructive analyst view. According to MarketBeat's consensus overview updated on September 18, 2026, Roche Holding AG's US-traded ADR (ticker RHHBY) carries an average 12-month price objective of USD60.00, based on ratings from 12 analysts.MarketBeat The same report states that six analysts currently rate the stock as a hold and six as a buy, resulting in a consensus recommendation of 'Moderate Buy' on the ADR.MarketBeat

The MarketBeat overview also outlines specific analyst actions that frame the risk-reward profile. It notes that Morgan Stanley recently upgraded Roche from an equal weight rating to overweight and set a price objective of USD63.00, signaling increased confidence in the company's earnings prospects and pipeline.MarketBeat The same source reports that Royal Bank of Canada initiated coverage with an outperform rating, while HSBC maintained a hold stance, highlighting that not all analysts see the stock as a clear buy at current levels.MarketBeat

For investors, the combination of a CHF364.80 closing price in Zurich on September 18, 2026, and a 33 percent share price increase over the past 12 months suggests that much of the recent good news may already be reflected in the valuation.Interactive Investor At the same time, the USD60.00 average ADR price target and the USD63.00 objective from Morgan Stanley indicate that analysts still see upside potential from current levels, assuming Roche can convert its regulatory and clinical wins into sustained earnings growth.MarketBeat

Pipeline momentum and partnership activity

The CHMP recommendation for paediatric Ocrevus comes amid a broader series of pipeline and partnership developments that underscore Roche's strategic focus on neurology and oncology. Morningstar's Roche quote page highlights several recent news items, including a Business Wire note on the grand opening of a Boston R&D innovation center for Genentech and Roche, which is intended to strengthen the group's early-stage research capabilities in the United States.Morningstar The same page lists a Business Wire announcement that a Lunsumio-based regimen significantly improved progression-free survival in follicular lymphoma in the phase 3 CELESTIMO study, reinforcing Roche's competitive position in hematology.Morningstar

A weekly biotech roundup from RTTNews reports that Dualitas Therapeutics has entered into a research collaboration and license agreement with Roche Holding AG to advance bispecific antibodies for immunology and inflammatory diseases, with a total potential deal value of up to USD1 billion including milestones and tiered royalties.RTTNews The same report notes that Roche's Lunsumio, in combination with lenalidomide, met its primary endpoint in the phase 3 CELESTIMO trial versus Rituxan plus lenalidomide in relapsed or refractory follicular lymphoma, which could support future label expansions and revenue growth if approved.RTTNews

BioWorld Asia separately reports that DualityBio has agreed a collaboration with Roche's Genentech unit focused on next-generation antibody-drug conjugate candidates, with a potential deal value exceeding USD1 billion and USD45 million paid upfront, underscoring Roche's willingness to invest heavily in innovative oncology platforms.BioWorld Asia For investors, these pipeline and partnership updates provide context for the CHMP opinion on paediatric Ocrevus: they illustrate how Roche is attempting to diversify its growth drivers across neurology, hematology and oncology, which may help support earnings and justify current valuation multiples over the medium term.

Roche stock level and investor takeaway

As of the last completed trading day, September 18, 2026, the reference price for Roche Holding stock on its primary listing venue SIX Swiss Exchange can be taken as CHF364.80, the closing level quoted in the Interactive Investor note on the CHMP decision, with the shares down 1.0 percent for that day but up 33 percent over 12 months.Interactive Investor Against a 52-week high of CHF375.80, reached on August 26, 2026, the current level leaves modest room for further gains if the regulatory momentum around Ocrevus, combined with partnerships such as those with Dualitas Therapeutics and DualityBio, translates into sustained growth in revenue and earnings over the coming years.finanzen.ch

More news and analyses on Roche Holding stock